NRSNW

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm dedicated to pioneering novel therapies for severe neurodegenerative conditions. Its most advanced investigational asset is PrimeC, an innovative oral compound specifically engineered to address amyotrophic lateral sclerosis (ALS). Beyond its lead program, the company boasts a preclinical pipeline featuring StabiliC, aimed at Parkinson's disease, and CogniC, targeting Alzheimer's disease. Established in Herzliya, Israel, in 2017, NeuroSense Therapeutics continues to advance its therapeutic initiatives.

CEO: Alon Ben-Noon
IPO Date: Dec 9, 2021

Market Data

Open: $0.17
High: $0.19
Low: $0.1451
Volume: 256
52W High: $0.30
52W Low: $0.1451

Valuation

Market Cap: $3.6M
Enterprise Value: $19M

Financials

Free Cash Flow: $-7.7M
Revenue: $0
Net Income: $-11M
Cash: $166k
Debt: $170k

Events

EarningsJun 22

EPS est. -0.0847